Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: An Australian and New Zealand Gynaecological Oncology Group study

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 359-366

  Harnett, P ^a   Buck, M ^b   Beale, P ^c   Goldrick, A ^d   Allan, S ^e   Fitzharris, B ^f   De Souza, P ^g   Links, M ^g   Kalimi, G ^h   Davies, T ⁱ   Stuart Harris, R ^j  

^a WESTMEAD HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e PALMERSTON NORTH HOSPITAL   (New Zealand)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g ST GEORGE HOSPITAL   (Australia)

^h ELI LILLY AND COMPANY   (United States)

ⁱ ELI LILLY AUSTRALIA PTY LTD   (Australia)

^j CANBERRA HOSPITAL   (Australia)

more..

Author keywords

Gemcitabine; Oxaliplatin; Phase II; Recurrent ovarian

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ARTICLE; AUSTRALIA; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEW ZEALAND; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CA-125 ANTIGEN; CARCINOMA; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW ZEALAND; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 33947197744     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00763.x     Document Type: Article

References (33)

1. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 2005;15(Suppl. 3):212-20.
2. Poveda A. Ovarian cancer: is the news good enough? Int J Gynecol Cancer 2005;15(Suppl. 3):298-306.
3. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992;10:513-4.
4. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
5. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 1999;22:450-2.
6. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
7. Hansen SW, Tuxen MK, Sessa C. Gemcitabine in the treatment of ovarian cancer (review). Ann Oncol 1999;10(Suppl. 1):51-3.
8. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343-5.
9. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
10. Woynarowski JM, Faivre S, Herzig MC et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-7.
11. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A. The role of the DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
12. Bible KC, Boerner SA, Kirkland K et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000;6:661-70.
13. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
14. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
15. van Moorsel CJ, Pinedo HM, Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer lines. Br J Cancer 1999;80:981-90.
16. Faivre S, Raymond E, Rixe O et al. Preclinical synergy of oxaliplatin in combination with other antitumor agents [abstract]. Ann Oncol 1998;9(Suppl. 4):131. Abstract 627P.
17. Mavroudis D, Kourousis C, Kakolyris S et al. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 2000;27(1. Suppl. 2):25-30.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
19. Rustin GJS, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-9.
20. Parmar MK, Ledermann JA, Colombo N et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-3106.
21. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. J Clin Oncol 2004 (ASCO Annual Meeting Proceedings). 2004;23:449. Abstract 5005.
22. Gonzalez-Martin A; GEICO Group. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 2005;15(Suppl. 3):241-6.
23. Papadimitriou CA, Fountzilas G, Aravantinos G et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study. Gynecol Oncol 2004;92:152-9.
24. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005;16:749-55.
25. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8.
26. Sessa C, Marsoni S. Randomized single-agents trials in recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl. 3):247-51.
27. Ozols RF. Gemcitabine and carboplatin in second-line ovarian cancer. Semin Oncol 2005;32(4. Suppl. 6):S4-8.
28. Dieras V, Bougnoux P, Petit T et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Ann Oncol 2002;13:258- 66.
29. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peter GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30.
30. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000;6:773-81.
31. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 2004;95:165-72.
32. Sundar S, Symonds RP, Decatris MP et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 2004;94:502-8.
33. Gan HK, Mitchell PL, Galettis P et al. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemother Pharmacol 2006;58:157-64.